Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) CEO Chad Robins sold 53,083 shares of the firm's stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $15.52, for a total transaction of $823,848.16. Following the completion of the sale, the chief executive officer owned 1,934,247 shares in the company, valued at $30,019,513.44. The trade was a 2.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Adaptive Biotechnologies Trading Down 0.2%
Shares of NASDAQ ADPT opened at $16.08 on Wednesday. Adaptive Biotechnologies Corporation has a 12-month low of $6.26 and a 12-month high of $20.76. The company has a market cap of $2.48 billion, a PE ratio of -40.20 and a beta of 2.19. The stock has a 50 day simple moving average of $16.85 and a 200-day simple moving average of $15.79.
Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last posted its earnings results on Thursday, February 5th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.10. The firm had revenue of $71.68 million for the quarter, compared to analysts' expectations of $59.38 million. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The firm's revenue was up 51.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.23) EPS. Sell-side analysts forecast that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
ADPT has been the subject of several research analyst reports. Guggenheim upped their price objective on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a "buy" rating in a report on Monday, January 26th. Piper Sandler set a $21.00 price target on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Adaptive Biotechnologies in a research note on Wednesday, January 21st. JPMorgan Chase & Co. raised their price objective on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an "overweight" rating in a research note on Friday, February 6th. Finally, Wall Street Zen raised Adaptive Biotechnologies from a "hold" rating to a "buy" rating in a report on Sunday, February 8th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $18.25.
View Our Latest Report on Adaptive Biotechnologies
Hedge Funds Weigh In On Adaptive Biotechnologies
Large investors have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd bought a new stake in shares of Adaptive Biotechnologies in the 4th quarter worth approximately $28,000. Sound Income Strategies LLC acquired a new position in Adaptive Biotechnologies in the third quarter worth approximately $30,000. EverSource Wealth Advisors LLC increased its holdings in shares of Adaptive Biotechnologies by 197.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company's stock valued at $38,000 after buying an additional 1,565 shares in the last quarter. Assetmark Inc. increased its holdings in shares of Adaptive Biotechnologies by 867.9% in the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company's stock valued at $49,000 after buying an additional 2,708 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. acquired a new stake in shares of Adaptive Biotechnologies during the 4th quarter valued at $51,000. Institutional investors own 99.17% of the company's stock.
About Adaptive Biotechnologies
(
Get Free Report)
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
